Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 251 to 275 of 285

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance and quality standards awaiting development
Title	Type
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis (ID1396)	Technology appraisal guidance
Tolebrutinib for treating relapsing multiple sclerosis ID6351	Technology appraisal guidance
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]	Technology appraisal guidance
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy TS ID 12119	Technology appraisal guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910	Technology appraisal guidance
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]	Technology appraisal guidance
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]	Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia ID 6456	Technology appraisal guidance
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781	Technology appraisal guidance
Upadacitinib for treating giant cell arteritis [ID6299]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468	Technology appraisal guidance
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]	Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815	Technology appraisal guidance

Results per page

10
25
50
All